Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Baxter
Johnson and Johnson
Express Scripts
Moodys

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Ibudilast


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Ibudilast?

Ibudilast is an investigational drug.

There have been 19 clinical trials for Ibudilast. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2020.

The most common disease conditions in clinical trials are Sclerosis, Alcohol Drinking, and Motor Neuron Disease. The leading clinical trial sponsors are MediciNova, University of California, Los Angeles, and National Institute on Drug Abuse (NIDA).

There are eight hundred and seven US patents protecting this investigational drug and seven international patents.

Recent Clinical Trials for Ibudilast
TitleSponsorPhase
Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDSMediciNovaPhase 2
Regeneration in Cervical Degenerative MyelopathyCambridge University Hospitals NHS Foundation TrustPhase 3
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSMediciNovaPhase 2/Phase 3

See all Ibudilast clinical trials

Clinical Trial Summary for Ibudilast

Top disease conditions for Ibudilast
Top clinical trial sponsors for Ibudilast

See all Ibudilast clinical trials

US Patents for Ibudilast

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ibudilast ⤷  Try it Free Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP) ⤷  Try it Free
Ibudilast ⤷  Try it Free Therapeutic approaches for treating Parkinson's disease Pharnext (Issy les Moulineaux, FR) ⤷  Try it Free
Ibudilast ⤷  Try it Free Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells Selecta Biosciences, Inc. (Watertown, MA) ⤷  Try it Free
Ibudilast ⤷  Try it Free Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag The Catholic University of America (Washington, DC) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ibudilast

Drugname Country Document Number Estimated Expiration Related US Patent
Ibudilast Canada CA2961033 2034-09-11 ⤷  Try it Free
Ibudilast European Patent Office EP3192791 2034-09-11 ⤷  Try it Free
Ibudilast Japan JPWO2016039408 2034-09-11 ⤷  Try it Free
Ibudilast World Intellectual Property Organization (WIPO) WO2016039408 2034-09-11 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Baxter
Johnson and Johnson
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.